Table 2.
Correlation of cytoplasmic TIMP3 and miR-222 with clinicopathologic parameters
| Groups | cTIMP3
|
P-value | cmiR-222
|
P-value | ||
|---|---|---|---|---|---|---|
| − | + | − | + | |||
| Gender | 1.0000 | 1.0000 | ||||
| Male | 71 | 42 | 51 | 62 | ||
| vFemale | 73 | 44 | 52 | 65 | ||
| Age (years) | 0.4139 | 0.5074 | ||||
| <55 | 68 | 46 | 54 | 60 | ||
| ≥55 | 76 | 40 | 49 | 67 | ||
| Smoking index | 0.5866 | 0.5960 | ||||
| <400 | 71 | 46 | 50 | 67 | ||
| ≥400 | 73 | 40 | 53 | 60 | ||
| Histological type | 0.8914 | 0.2316 | ||||
| SCC | 78 | 45 | 60 | 63 | ||
| AD | 66 | 41 | 43 | 64 | ||
| TNM staging | <0.0001 | <0.0001 | ||||
| IA–IIB | 63 | 66 | 85 | 44 | ||
| IIIA–IV | 81 | 20 | 18 | 83 | ||
Abbreviations: AD, adenocarcinoma; miR-222, microRNA-222; SCC, squamous cell carcinoma; TIMP3, matrix metalloproteinase inhibitor 3.